相关实验视频

Updated: Jul 1, 2025

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

在阿拉伯联合长国的COVID-19大流行之前和期间,人类白蛋白溶液的利用模式:是时候制定和实施关于处方和利用的国家指南了

Mohammed Sallam¹, Johan Snygg^2,3

¹Department of Pharmacy, Mediclinic Welcare Hospital, Mediclinic Middle East, Dubai, United Arab Emirates.

|March 7, 2024

概括

人类白蛋白溶液 (HAS) 的使用在COVID-19期间显著增加,尽管有指导方针,但没有明显的临床益处. 这项研究强调了需要更严格的协议来合理化HAS管理和降低成本.

科学领域:

临床药房临床药房
医疗保健管理的管理

背景情况:

人类白蛋白溶液 (HAS) 具有特定的临床适用性,但容易导致不适当和昂贵的使用.
建立HAS使用的实用协议对于成本效益和患者护理至关重要.

研究的目的:

在COVID-19大流行之前和期间分析迪拜医院HAS利用模式.
评估HAS规范策略的适当性,并确定需要改进的领域.

主要方法:

在Mediclinic Welcare医院对20%的HAS进行了回顾性数据收集 (2019年1月 - 2021年5月).
包括579名患者入院,分析初级诊断和使用量.
在COVID-19和COVID-19前阶段之间的HAS利用率和临床指示百分比的比较.

主要成果:

临床上表明的20%的HAS管理从COVID-19前的13.0%下降到大流行期间的1.5% (p<0.001).
不基于证据的HAS管理的增加与阿联COVID-19病例的增加有关.
在COVID-19期间HAS管理的显著增加缺乏支持的临床证据.

结论:

在COVID-19期间,HAS使用量大幅增加,但没有记录的临床益处.
建议完善机构指导方针,进行审计和实施教育干预措施,以优化HAS使用.
改进的HAS管理指南可以减轻与不适当使用相关的成本.

关键词:

人类白蛋白的人类白蛋白.临床药房临床药房使用药物使用药物使用.准则准则准则准则医疗保健医疗保健医疗保健医疗保健

更多相关视频

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications

Published on: October 20, 2023

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Published on: February 16, 2022

相关概念视频

Drug Distribution: Plasma Protein Binding

Drug Distribution: Plasma Protein Binding

Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...